Published in Drug Week, July 2nd, 2010
"The absolute configuration of the target compound 23 alpha was confirmed by X-ray crystallography," wrote L.Q. Cong and colleagues.
The researchers concluded: "The antitumor activities of the target compounds were tested against the growth of human carcinoma of colon (LOVO), human leukemia cell line (CEM) and human breast cancer cell line (MDA-MB-435) cells in vitro. 6-cyclopentylamino and 6-cyclohexylamino purine compounds 26 and 27, both in alpha-configuration and in beta-form, exhibited strong inhibition...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.